Victor S. Gurevich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Victor S. Gurevich has a total of 450 co-authors. Here are the top co-authors by number of shared publications:
- Igor V. Sergienko
National Medical Research Center of Cardiology named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, Moscow
11 shared publications - Soreiia A. Urazgildeeva
Center for Atherosclerosis and Lipid Metabolism Disorders of L. G. Sokolov Northwest District Scientific and Clinical Center, 194291 Saint Petersburg, Russia
10 shared publications - Marat V. Ezhov
A.L. Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology n.a. acad. E.I. Chazov, Ministry of Health of the Russian Federation, Moscow 121552, Russia
9 shared publications - Albert S. Galyavich
Kazan State Medical University
8 shared publications I A Mikhaĭlova
8 shared publicationsIu G Popov
6 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 6, 1003257
Potential molecular mimicry of proteins involved in atherogenesis and/or vasculitides with coronavirus antigens
Aim: This study explores the pathogenesis of atherosclerosis, as well as the comorbidity of atherosclerosis and coronavirus infection. The objective of the article is to provide a rationale for the potential involvement of an autoimmune component in the observed comorbidity between these two conditions. Methods: The research utilized bioinformatic and laboratory techniques. The bioinformatic approach involved selecting 30 human autoantigens, either proven or hypothesized to participate in atherogenesis and/or arteritides, as well as the most immunogenic proteins from human coronavirus antigens. To identify shared minimal immunogenic determinants (pentapeptides) between human autoantigens and coronavirus antigens, the proprietary “Alignmentaj” program was employed. Antibody levels against apolipoprotein B-100 (ApoB-100) and Proteinase 3 (PR3) were measured using enzyme-linked immunosorbent assay (ELISA) in patients with cardiovascular disease following coronavirus disease 2019 (COVID-19). Post-mortem tissue samples were subjected to standard morphological examination, supplemented with immunohistochemical methods for pathomorphological analysis. Results: The analysis revealed that the spike protein of human coronaviruses exhibits the highest concentration of pentapeptides similar to those found in atherogenesis-associated proteins. Notably, ApoB-100 shared the greatest number of peptides. Post-COVID cardiovascular patients showed varied anti-ApoB antibody and anti-PR3 antibody levels and potential complications. Pathomorphological examination of the aorta and coronary arteries of patients who died from atherothrombotic complications following COVID-19 infection revealed signs of autoimmune inflammation. Lymphocytic infiltration, consisting of T-cells and B-cells, as well as indications of vasa vasorum vasculitis, were observed in areas of unstable aortic atherosclerotic plaques and in the adventitia of coronary arteries. Conclusions: The identified sequence homology between human coronavirus antigens and human autoantigens, together with laboratory data obtained from patients with cardiovascular pathology following COVID-19, supports the hypothesis that molecular mimicry contributes to the initiation or exacerbation of atherosclerotic cardiovascular disease in the post-COVID period.
- 1 July 2026
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 6, 1003257
Open AccessPotential molecular mimicry of proteins involved in atherogenesis and/or vasculitides with coronavirus antigens
Aim: This study explores the pathogenesis of atherosclerosis, as well as the comorbidity of atherosclerosis and coronavirus infection. The objective of the article is to provide a rationale for the potential involvement of an autoimmune component in the observed comorbidity between these two conditions. Methods: The research utilized bioinformatic and laboratory techniques. The bioinformatic approach involved selecting 30 human autoantigens, either proven or hypothesized to participate in atherogenesis and/or arteritides, as well as the most immunogenic proteins from human coronavirus antigens. To identify shared minimal immunogenic determinants (pentapeptides) between human autoantigens and coronavirus antigens, the proprietary “Alignmentaj” program was employed. Antibody levels against apolipoprotein B-100 (ApoB-100) and Proteinase 3 (PR3) were measured using enzyme-linked immunosorbent assay (ELISA) in patients with cardiovascular disease following coronavirus disease 2019 (COVID-19). Post-mortem tissue samples were subjected to standard morphological examination, supplemented with immunohistochemical methods for pathomorphological analysis. Results: The analysis revealed that the spike protein of human coronaviruses exhibits the highest concentration of pentapeptides similar to those found in atherogenesis-associated proteins. Notably, ApoB-100 shared the greatest number of peptides. Post-COVID cardiovascular patients showed varied anti-ApoB antibody and anti-PR3 antibody levels and potential complications. Pathomorphological examination of the aorta and coronary arteries of patients who died from atherothrombotic complications following COVID-19 infection revealed signs of autoimmune inflammation. Lymphocytic infiltration, consisting of T-cells and B-cells, as well as indications of vasa vasorum vasculitis, were observed in areas of unstable aortic atherosclerotic plaques and in the adventitia of coronary arteries. Conclusions: The identified sequence homology between human coronavirus antigens and human autoantigens, together with laboratory data obtained from patients with cardiovascular pathology following COVID-19, supports the hypothesis that molecular mimicry contributes to the initiation or exacerbation of atherosclerotic cardiovascular disease in the post-COVID period.
- 1 June 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (4) , 919-930
An International, Multi-Specialty Consensus Document on the Optimal Management of Patients with Internal Carotid Artery Occlusion
- 1 June 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (4) , 919-930
An International, Multi-Specialty Consensus Document on the Optimal Management of Patients with Internal Carotid Artery Occlusion
- 30 January 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (11)
Expert consensus on the management of patients with cerebrovascular diseases and lipid metabolism disorders: focus on primary and secondary prevention
This consensus provides valuable advice on the clinical management of patients and the interpretation of research data in areas not covered by clinical guidelines. It is intended for neurologists, cardiologists, and general practitioners. It combines data from modern studies on the risk of cognitive impairment and stroke in patients with lipid metabolism disorders. Approaches and algorithms for hypertriglyceridemia correction as part of the primary and secondary prevention of diseases associated with cerebrovascular diseases and atherosclerosis were developed.
- 30 January 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (11)
Expert consensus on the management of patients with cerebrovascular diseases and lipid metabolism disorders: focus on primary and secondary prevention
This consensus provides valuable advice on the clinical management of patients and the interpretation of research data in areas not covered by clinical guidelines. It is intended for neurologists, cardiologists, and general practitioners. It combines data from modern studies on the risk of cognitive impairment and stroke in patients with lipid metabolism disorders. Approaches and algorithms for hypertriglyceridemia correction as part of the primary and secondary prevention of diseases associated with cerebrovascular diseases and atherosclerosis were developed.
- 21 November 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (10)
Genetic architecture of familial hypercholesterolemia: a cohort of St. Petersburg residents
Aim. To determine the frequency of pathogenic and likely pathogenic variants associated with familial hypercholesterolemia (FH) with assessment of the proportion of polygenic FH according to the 6-SNP genetic risk score (GRS) among patients diagnosed with possible/probable/definite FH in St. Petersburg. Material and methods. This study tested a hybrid targeted panel for gene diagnostics of hereditary dyslipidemias, including an expanded list of genes associated with monogenic dyslipidemias and a number of single-nucleotide variants associated with polygenic hypercholesterolemia and cardiovascular risk. Genetic testing was performed on 125 patients. Results. A total of 26 pathogenic and likely pathogenic variants in the LDLR gene were identified in 38 patients, while 6 variants of uncertain clinical significance in the LDLR gene — in 7 patients, and a pathogenic variant 10580G>A (p.Arg3527G) in the APOB gene — in 6 patients. The highest detection rate of causal genetic variants (66,7%) was observed, as expected, in the subgroup of patients with definite FH. Patients with a high polygenic risk of hypercholesterolemia predominated in the subgroups diagnosed with possible and probable FH. Conclusion. The use of an expanded next-generation sequencing (NGS) panel, including genes for hereditary dyslipidemias, as well as loci for calculating the GRS, may be critical for differential diagnosis, determining the etiology of hypercholesterolemia, and personalizing treatment approaches.
- 21 November 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (10)
Genetic architecture of familial hypercholesterolemia: a cohort of St. Petersburg residents
Aim. To determine the frequency of pathogenic and likely pathogenic variants associated with familial hypercholesterolemia (FH) with assessment of the proportion of polygenic FH according to the 6-SNP genetic risk score (GRS) among patients diagnosed with possible/probable/definite FH in St. Petersburg. Material and methods. This study tested a hybrid targeted panel for gene diagnostics of hereditary dyslipidemias, including an expanded list of genes associated with monogenic dyslipidemias and a number of single-nucleotide variants associated with polygenic hypercholesterolemia and cardiovascular risk. Genetic testing was performed on 125 patients. Results. A total of 26 pathogenic and likely pathogenic variants in the LDLR gene were identified in 38 patients, while 6 variants of uncertain clinical significance in the LDLR gene — in 7 patients, and a pathogenic variant 10580G>A (p.Arg3527G) in the APOB gene — in 6 patients. The highest detection rate of causal genetic variants (66,7%) was observed, as expected, in the subgroup of patients with definite FH. Patients with a high polygenic risk of hypercholesterolemia predominated in the subgroups diagnosed with possible and probable FH. Conclusion. The use of an expanded next-generation sequencing (NGS) panel, including genes for hereditary dyslipidemias, as well as loci for calculating the GRS, may be critical for differential diagnosis, determining the etiology of hypercholesterolemia, and personalizing treatment approaches.
- Open Access
- 22 August 2025
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (3) , 244-256
Effectiveness of fixed-dose combination of rosuvastatin and ezetimibe in heterozygous familial hypercholesterolemia from the RENAISSANCE registry
Aim. To study the adequacy and effectiveness of lipid-lowering therapy (LLT) prescribed to patients with heterozygous familial hypercholesterolemia (HeFH), including fixed-dose combinations (FDC) of rosuvastatin with ezetimibe, as well as the frequency of achieving target low-density lipoprotein cholesterol (LDL-C) levels.Material and methods. The clinical and demographic data of 3151 patients with HeFH at high or very high cardiovascular risk from the RENAISSANCE registry were retrospectively analysed. Among the 1612 individuals receiving LLT, 477 patients were treated with a combination of rosuvastatin at various doses and ezetimibe 10 mg daily, either as a free combination or as a FDC.Results. The median age of the patients was 46.0 [32.0; 57.0] years. The median LDL-C level was 6.4 [5.3; 7.8] mmol/L. Although LLT was recommended to all participants, approximately half (49%, n=1539) were not receiving treatment. Among the 1612 patients on LLT, 44% (n=703) received statin monotherapy, and 43% (n=697) were treated with a combination of statins and ezetimibe. Of the 477 patients taking rosuvastatin with ezetimibe, the majority were active adults of working age (35-64 years): 335 (80%) vs 86 (20%), p Conclusion. Among patients with НeFH, the use of a FDC of rosuvastatin and ezetimibe is associated with higher treatment adherence and a greater likelihood of achieving target LDL-С levels.
- 22 August 2025
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (3) , 244-256
Open AccessEffectiveness of fixed-dose combination of rosuvastatin and ezetimibe in heterozygous familial hypercholesterolemia from the RENAISSANCE registry
Aim. To study the adequacy and effectiveness of lipid-lowering therapy (LLT) prescribed to patients with heterozygous familial hypercholesterolemia (HeFH), including fixed-dose combinations (FDC) of rosuvastatin with ezetimibe, as well as the frequency of achieving target low-density lipoprotein cholesterol (LDL-C) levels.Material and methods. The clinical and demographic data of 3151 patients with HeFH at high or very high cardiovascular risk from the RENAISSANCE registry were retrospectively analysed. Among the 1612 individuals receiving LLT, 477 patients were treated with a combination of rosuvastatin at various doses and ezetimibe 10 mg daily, either as a free combination or as a FDC.Results. The median age of the patients was 46.0 [32.0; 57.0] years. The median LDL-C level was 6.4 [5.3; 7.8] mmol/L. Although LLT was recommended to all participants, approximately half (49%, n=1539) were not receiving treatment. Among the 1612 patients on LLT, 44% (n=703) received statin monotherapy, and 43% (n=697) were treated with a combination of statins and ezetimibe. Of the 477 patients taking rosuvastatin with ezetimibe, the majority were active adults of working age (35-64 years): 335 (80%) vs 86 (20%), p Conclusion. Among patients with НeFH, the use of a FDC of rosuvastatin and ezetimibe is associated with higher treatment adherence and a greater likelihood of achieving target LDL-С levels.
- Open Access
- 27 July 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (3) , 192-218
Hypertriglyceridemia (triglyceride-rich lipoproteins and their remnants): role in development of atherosclerotic cardiovascular diseases and control strategy consensus statement of the expert Committee of the Russian Society of Cardiology (RSC), the National Atherosclerosis Society (NAS), and the Russian Society of Cardiovascular Prevention and Rehabilitation (RosOKR)
This expert consensus document discusses the high prevalence of cardiovascular diseases (CVDs) caused by atherosclerosis. It is now evident that the causes and pathogenesis of atherosclerotic cardiovascular diseases (ASCVD) cannot always be explained solely by lipid metabolism disorders associated with low-density lipoproteins (LDL). In recent years, an increasing number of studies have focused on hypertriglyceridemia (HTG), including its mechanisms and role in atherothrombogenesis. In this regard, it has become necessary to update key aspects that define the root causes of ASCVD in HTG and the role of triglyceride-rich lipoproteins (TRLs) and their remnants in this process. Epidemiologic and genetic studies have demonstrated a causal relationship between HTG and the development of ASCVD, independent of LDL-C levels. The role of TRLs in determining high residual cardiovascular risk under conditions of LDL-C control has been established, and evidence has been obtained supporting the preventive benefits of lowering elevated plasma triglyceride levels. This document presents the consensus positions of experts regarding the classification, etiology, and mechanisms of HTG, the importance of assessing TRLs/remnants, and a detailed discussion of their metabolism and pathophysiologic role in atherothrombosis. The experts also address the clinical assessment and patient management pathways for HTG, outlining both nonpharmacologic and pharmacologic strategies for its correction.
- 27 July 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (3) , 192-218
Open AccessHypertriglyceridemia (triglyceride-rich lipoproteins and their remnants): role in development of atherosclerotic cardiovascular diseases and control strategy consensus statement of the expert Committee of the Russian Society of Cardiology (RSC), the National Atherosclerosis Society (NAS), and the Russian Society of Cardiovascular Prevention and Rehabilitation (RosOKR)
This expert consensus document discusses the high prevalence of cardiovascular diseases (CVDs) caused by atherosclerosis. It is now evident that the causes and pathogenesis of atherosclerotic cardiovascular diseases (ASCVD) cannot always be explained solely by lipid metabolism disorders associated with low-density lipoproteins (LDL). In recent years, an increasing number of studies have focused on hypertriglyceridemia (HTG), including its mechanisms and role in atherothrombogenesis. In this regard, it has become necessary to update key aspects that define the root causes of ASCVD in HTG and the role of triglyceride-rich lipoproteins (TRLs) and their remnants in this process. Epidemiologic and genetic studies have demonstrated a causal relationship between HTG and the development of ASCVD, independent of LDL-C levels. The role of TRLs in determining high residual cardiovascular risk under conditions of LDL-C control has been established, and evidence has been obtained supporting the preventive benefits of lowering elevated plasma triglyceride levels. This document presents the consensus positions of experts regarding the classification, etiology, and mechanisms of HTG, the importance of assessing TRLs/remnants, and a detailed discussion of their metabolism and pathophysiologic role in atherothrombosis. The experts also address the clinical assessment and patient management pathways for HTG, outlining both nonpharmacologic and pharmacologic strategies for its correction.
- Open Access
- 2 June 2025
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 6-34
Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
Cardiovascular diseases are one of the main causes of mortality and disability among the population of the member countries of the Eurasian Association of Cardiology, which is directly related to the high prevalence of risk factors for atherosclerosis, among which dyslipidemia plays a leading role. The previous version of the Eurasian Recommendations for the Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis was presented in 2020. Over the past 5 years, approaches to risk stratification, diagnosis of subclinical atherosclerosis, and correction of dyslipidemia using various classes of lipid-lowering drugs have changed significantly. Among the initial updates, proposals should be highlighted for determining the blood lipid level in each adult or upon reaching the age of 18, using the SCORE and/or SCORE2 scales to stratify cardiovascular risk, and non-invasive imaging techniques to assess subclinical atherosclerosis. In the sections devoted to therapy, fixed combinations of lipid-lowering drugs, inclisiran, and bempedoic acid are presented. The section on the prevalence, significance and approaches to correction of hypertriglyceridemia, as well as the section on extracorporeal hemocorrection, has been expanded. A chapter on lipoprotein(a) is introduced. Sections on correction of dyslipidemia in cerebrovascular diseases, heart transplantation and HIV infection are presented. These recommendations will be useful to the phisicians of all specialties for the effective management of their patients.
- 2 June 2025
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 6-34
Open AccessEurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
Cardiovascular diseases are one of the main causes of mortality and disability among the population of the member countries of the Eurasian Association of Cardiology, which is directly related to the high prevalence of risk factors for atherosclerosis, among which dyslipidemia plays a leading role. The previous version of the Eurasian Recommendations for the Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis was presented in 2020. Over the past 5 years, approaches to risk stratification, diagnosis of subclinical atherosclerosis, and correction of dyslipidemia using various classes of lipid-lowering drugs have changed significantly. Among the initial updates, proposals should be highlighted for determining the blood lipid level in each adult or upon reaching the age of 18, using the SCORE and/or SCORE2 scales to stratify cardiovascular risk, and non-invasive imaging techniques to assess subclinical atherosclerosis. In the sections devoted to therapy, fixed combinations of lipid-lowering drugs, inclisiran, and bempedoic acid are presented. The section on the prevalence, significance and approaches to correction of hypertriglyceridemia, as well as the section on extracorporeal hemocorrection, has been expanded. A chapter on lipoprotein(a) is introduced. Sections on correction of dyslipidemia in cerebrovascular diseases, heart transplantation and HIV infection are presented. These recommendations will be useful to the phisicians of all specialties for the effective management of their patients.
- 28 April 2025
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 28 (4)
The place of non-high-density lipoprotein cholesterol and triglycerides in the assessment of cardiovascular risk: Resolution of the Panel of Experts
The main focus for reducing the incidence of cardiovascular diseases (CVD) associated with atherosclerosis is early stratification of the CVD risk, timely detection of lipid metabolism disorders, and medical care for patients with a high and very high risk of developing such diseases. High-density lipoprotein cholesterol (HDL-C) was previously considered a risk factor for atherosclerosis; however, recently, high triglycerides and non-high-density lipoprotein cholesterol (NHDL-C) have also become important risk factors. This Resolution of the Panel of Experts reflects the roles of triglycerides and non-HDL cholesterol in cardiovascular risk assessment.
- 28 April 2025
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 28 (4)
The place of non-high-density lipoprotein cholesterol and triglycerides in the assessment of cardiovascular risk: Resolution of the Panel of Experts
The main focus for reducing the incidence of cardiovascular diseases (CVD) associated with atherosclerosis is early stratification of the CVD risk, timely detection of lipid metabolism disorders, and medical care for patients with a high and very high risk of developing such diseases. High-density lipoprotein cholesterol (HDL-C) was previously considered a risk factor for atherosclerosis; however, recently, high triglycerides and non-high-density lipoprotein cholesterol (NHDL-C) have also become important risk factors. This Resolution of the Panel of Experts reflects the roles of triglycerides and non-HDL cholesterol in cardiovascular risk assessment.
- Open Access
- 18 March 2025
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 53 (1) , 43-52
Calculation formulas for low density lipoprotein cholesterol in cardiological practice: the more, the better?
Monitoring of low density lipoprotein cholesterol (LDL-C) levels is a key element of anti-atherogenic therapy in patients with atherosclerotic cardiovascular diseases, especially those at high and very high risk. The target LDL-C levels ( 1.8 mmol/L for high risk and 1.4 mmol/L for very high risk) are important indicators for quality of medical care. Traditionally, the Friedewald formula has been used to estimate LDL-C, but its accuracy is limited when triglyceride (TG) levels exceed 4.5 mmol/L. This article reviews current approaches to optimization of the LDL-C calculation formulas, their applicability in clinical practice, and regional variations. The Friedewald formula, proposed in 1972, has long been the primary method for LDL-C estimation. However, its limitations, particularly at high TG levels, have led to the development of alternative formulas, such as the Martin method and the Sampson formula. The Martin method, based on the analysis of over 1.35 million lipid profiles, suggests the use of correction factors depending on TG levels. The Sampson formula, which accounts for complex metabolic processes, demonstrates high accuracy, especially at TG levels 4.5 mmol/L. There are regional variations in lipid levels associated with climatic, cultural, and genetic factors. For example, in South Korea, a formula tailored to the local population has been proposed, showing higher accuracy compared to the Friedewald formula. In the Russian Federation, a formula based on the analysis of 750,000 lipid profiles has been developed, demonstrating high accuracy across a wide range of TG levels (0.1–30 mmol/L). These studies highlight the need to adapt calculation methods to local populations. In clinical practice, the choice of LDL-C calculation method depends on the study objectives and clinical characteristics of the disease. The American Heart Association (AHA) recommends the Martin method, while the National Institute of Health (NIH) favors the Sampson formula. In Russia, the Friedewald formula is still used, although its accuracy is questioned. In multicenter studies of lipid-lowering drugs, newer formulas are preferred, such as the NIH formula, which has shown high accuracy at low LDL-C levels. The need for accurate LDL-C determination to assess the cardiovascular risk and monitor the treatment efficacy drives the development of new calculation methods. The Friedewald formula, despite its widespread use, is less accurate than modern methods, especially at high TG levels. Optimization of the formulas to account for regional population characteristics seems an important step toward improvement of the quality of diagnosis and treatment of atherosclerotic diseases.
- 18 March 2025
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 53 (1) , 43-52
Open AccessCalculation formulas for low density lipoprotein cholesterol in cardiological practice: the more, the better?
Monitoring of low density lipoprotein cholesterol (LDL-C) levels is a key element of anti-atherogenic therapy in patients with atherosclerotic cardiovascular diseases, especially those at high and very high risk. The target LDL-C levels ( 1.8 mmol/L for high risk and 1.4 mmol/L for very high risk) are important indicators for quality of medical care. Traditionally, the Friedewald formula has been used to estimate LDL-C, but its accuracy is limited when triglyceride (TG) levels exceed 4.5 mmol/L. This article reviews current approaches to optimization of the LDL-C calculation formulas, their applicability in clinical practice, and regional variations. The Friedewald formula, proposed in 1972, has long been the primary method for LDL-C estimation. However, its limitations, particularly at high TG levels, have led to the development of alternative formulas, such as the Martin method and the Sampson formula. The Martin method, based on the analysis of over 1.35 million lipid profiles, suggests the use of correction factors depending on TG levels. The Sampson formula, which accounts for complex metabolic processes, demonstrates high accuracy, especially at TG levels 4.5 mmol/L. There are regional variations in lipid levels associated with climatic, cultural, and genetic factors. For example, in South Korea, a formula tailored to the local population has been proposed, showing higher accuracy compared to the Friedewald formula. In the Russian Federation, a formula based on the analysis of 750,000 lipid profiles has been developed, demonstrating high accuracy across a wide range of TG levels (0.1–30 mmol/L). These studies highlight the need to adapt calculation methods to local populations. In clinical practice, the choice of LDL-C calculation method depends on the study objectives and clinical characteristics of the disease. The American Heart Association (AHA) recommends the Martin method, while the National Institute of Health (NIH) favors the Sampson formula. In Russia, the Friedewald formula is still used, although its accuracy is questioned. In multicenter studies of lipid-lowering drugs, newer formulas are preferred, such as the NIH formula, which has shown high accuracy at low LDL-C levels. The need for accurate LDL-C determination to assess the cardiovascular risk and monitor the treatment efficacy drives the development of new calculation methods. The Friedewald formula, despite its widespread use, is less accurate than modern methods, especially at high TG levels. Optimization of the formulas to account for regional population characteristics seems an important step toward improvement of the quality of diagnosis and treatment of atherosclerotic diseases.
- Open Access
- 15 March 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (1) , 5-20
The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
The presented expert paper discusses the high prevalence of hypercholesterolemia (HCH) in Russia. Insufficient use of lipid-lowering therapy in both primary and secondary prevention is indicated. Failure to achieve the target level of low-density lipoprotein cholesterol (HC) and low adherence (especially long-term) of patients to hypolipidemic drugs remains a serious problem in real clinical practice. Statins are a class of widely prescribed lipid-lowering drugs that are the first choice drugs in the treatment of HCV and combined hyperlipidemia (GLP) with proven efficacy in the prevention of atherosclerotic cardiovascular diseases. Using the example of the original pitavastatin, this expert document convincingly demonstrates the drug's capabilities not only in reducing atherogenic lipids and lipoproteins in blood plasma, but also its clinical effectiveness in the primary and secondary prevention of cardiovascular complications. This highlights the unique effect of pitavastatin on increasing low cholesterol levels of high-density lipoproteins, proven anti-atherosclerotic activity and a wide range of positive pleiotropic effects that enhance its antiatherogenic effect. The low risk of drug interactions inherent in pitavastatin highlights its high safety with prolonged use and good tolerability. All of the above gives grounds to consider the original pitavastatin as the drug of choice for a wide range of patients. This article was previously published in: Bubnova MG, Galyavich AS, Ezhov MV, Aronov DM, Vinogradova NN, Galstyan GR, Gurevich VS, Karpov YuA, Koziolova NA, Kosmacheva ED, Matyushin GV, Sergienko IV, Filippov AE, Khalimov YuSh. The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists. Russian Journal of Cardiology. 2024;29(11):6148. doi: 10.15829/1560-4071-2024-6148. EDN: PSIJPF The article was published with the consent of the author's team and the editorial board of the Russian Journal of Cardiology and does not contradict the Creative Commons Attribution 4.0 License.
- 15 March 2025
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 16 (1) , 5-20
Open AccessThe place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists
The presented expert paper discusses the high prevalence of hypercholesterolemia (HCH) in Russia. Insufficient use of lipid-lowering therapy in both primary and secondary prevention is indicated. Failure to achieve the target level of low-density lipoprotein cholesterol (HC) and low adherence (especially long-term) of patients to hypolipidemic drugs remains a serious problem in real clinical practice. Statins are a class of widely prescribed lipid-lowering drugs that are the first choice drugs in the treatment of HCV and combined hyperlipidemia (GLP) with proven efficacy in the prevention of atherosclerotic cardiovascular diseases. Using the example of the original pitavastatin, this expert document convincingly demonstrates the drug's capabilities not only in reducing atherogenic lipids and lipoproteins in blood plasma, but also its clinical effectiveness in the primary and secondary prevention of cardiovascular complications. This highlights the unique effect of pitavastatin on increasing low cholesterol levels of high-density lipoproteins, proven anti-atherosclerotic activity and a wide range of positive pleiotropic effects that enhance its antiatherogenic effect. The low risk of drug interactions inherent in pitavastatin highlights its high safety with prolonged use and good tolerability. All of the above gives grounds to consider the original pitavastatin as the drug of choice for a wide range of patients. This article was previously published in: Bubnova MG, Galyavich AS, Ezhov MV, Aronov DM, Vinogradova NN, Galstyan GR, Gurevich VS, Karpov YuA, Koziolova NA, Kosmacheva ED, Matyushin GV, Sergienko IV, Filippov AE, Khalimov YuSh. The place of original pitavastatin in primary and secondary prevention of cardiovascular diseases. Interdisciplinary Expert Consensus of the Russian Society of Cardiology, the National Atherosclerosis Society, the Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, and the Russian Association of Endocrinologists. Russian Journal of Cardiology. 2024;29(11):6148. doi: 10.15829/1560-4071-2024-6148. EDN: PSIJPF The article was published with the consent of the author's team and the editorial board of the Russian Journal of Cardiology and does not contradict the Creative Commons Attribution 4.0 License.